NCT03081676View on ClinicalTrials.gov

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions

Maturity-Onset Diabetes of the Young, Type 3

Interventions

DRUG

Glimepiride 1Mg Tablet

Glimepiride

DRUG

Glucagon-like Peptide-1

GLP-1 infusion

DRUG

Glucose-Dependent Insulinotropic Polypeptide

GIP-infusion

DRUG

Placebo Oral Tablet

Placebo

DRUG

Placebo infusion

Placebo (saline)

Trial Locations (1)

2900

Center for Diabetes Research, Gentofte Hospital, Hellerup

All Listed Sponsors

lead

University Hospital, Gentofte, Copenhagen

OTHER

NCT03081676 - The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea | Biotech Hunter | Biotech Hunter